U.S. Stem Cell, Inc.
(Other OTC/NBB : USRM)

( )
USRM PreMarket: $ () as of AM
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield

Message Boards

...

News

...
Health Technology » Biotechnology

Company Profile

U.S. Stem Cell, Inc. operates as a biotechnology company focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage. Its business also includes the development of proprietary cell therapy products as well as revenue generating physician and patient based regenerative medicine & cell therapy training services, cell collection and cell storage services, the sale of cell collection and treatment kits for humans and animals, and the operation of a cell therapy clinic. The company was founded by Howard J. Leonhardt and Robert D. Lashinski on August 12, 1999 and is headquartered in Sunrise, FL.